The
calcium-sensing receptor (CaSR) is the main regulator of extracellular Ca2+ homeostasis. It has diverse functions in different tissues, including the intestines. Intestine-specific knockout of the CaSR renders mice more susceptible to
dextran sulphate
sodium (DSS)-induced
colitis. To test our hypothesis that the CaSR reduces intestinal
inflammation, we assessed the effects of nutritional and pharmacological agonists of the CaSR in a
colitis model. We treated female Balb/C mice with
dietary calcium and
protein (nutritional agonists of the CaSR) or pharmacological CaSR modulators (the agonists
cinacalcet and GSK3004774, and the antagonist
NPS-2143; 10 mg/kg), then induced
colitis with DSS. The
high-protein diet had a strong pro-inflammatory effect-it shortened the colons (5.3 ± 0.1 cm vs. 6.1 ± 0.2 cm normal diet, p < 0.05), lowered
mucin expression and upregulated pro-inflammatory
cytokines, such as
interferon-γ, (4.2-fold, p < 0.05) compared with the normal diet.
Cinacalcet reduced
mucin expression, which coincided with an increase in
tumor necrosis factor-α (4.4-fold, p < 0.05) and
IL-6 (4.9-fold, p < 0.05) in the plasma, compared with vehicle. The CaSR antagonist, NPS-2143, significantly reduced the cumulative
inflammation score compared with the vehicle control (35.3 ± 19.1 vs. 21.9 ± 14.3 area under the curve, p < 0.05) and reduced infiltration of inflammatory cells. While dietary modulation of the CaSR had no beneficial effects, pharmacological inhibition of the CaSR may have the potential of a novel add-on
therapy in the treatment of
inflammatory bowel diseases.